Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

TIII Over TI in Subjects With Myocardial Infarction

Condition:   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Other: Non interventional study
Sponsor:   University of Cologne
Completed - verified February 2017

Henry Ford Heart Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction

Conditions:   Chest Pain;   Heart Attack;   Coronary Artery Disease
Intervention:   Other: Deferral of admission for stress test
Sponsor:   Henry Ford Health System
Completed - verified February 2017

EROSION II: OCT Guided PPCI in STEMI

Condition:   STEMI - ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   Harbin Medical University
Recruiting - verified February 2017

The Impact of Depression and/or Anxiety on PCI Patients

Conditions:   Acute Coronary Syndrome;   MAjor Depressive Disorder;   Generalized Anxiety Disorder
Intervention:   Other: antidepressive and anti-anxiety therapy
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Xi'an Central Hospital;   Baoji Central Hospital;   Baoji People's Hospital;   General Hospital of Ningxia Medical University;   The People's Hospital of Ningxia;   Wuzhong People's Hospital;   The First Hospital of Lanzhou University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   the People's Hospital of Xinjiang Uygur Autonomous Region;   The First People's Hospital of Kashgar Erea;   the First Division Hospital of Xinjiang Production and Construction Corps
Not yet recruiting - verified December 2016

Low-dose of Ticagrelor and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease

Conditions:   Coronary Artery Disease;   Clopidogrel, Poor Metabolism of
Interventions:   Drug: Clopidogrel;   Drug: ticagrelor
Sponsor:   First Affiliated Hospital of Harbin Medical University
Recruiting - verified February 2017

System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)

Condition:   Coronary Heart Disease
Intervention:   Procedure: Reperfusion
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Enrolling by invitation - verified February 2017

Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: Colchicine;   Drug: Spironolactone;   Device: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent;   Drug: Colchicine-Placebo;   Drug: Spironolactone-Placebo
Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR);   Boston Scientific Corporation
Not yet recruiting - verified February 2017

Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation

Conditions:   Coronary Artery Disease;   Aortic Valve Stenosis;   TAVI;   PCI
Intervention:   Procedure: PCI
Sponsors:   Rigshospitalet, Denmark;   Aarhus University Hospital;   Aalborg Universitetshospital;   Odense University Hospital;   Lund University Hospital;   Karolinska University Hospital;   Rikshospitalet University Hospital;   Haukeland University Hospital;   Helsinki University Central Hospital;   Tampere University Hospital;   Oulu University Hospital
Not yet recruiting - verified February 2017

Ferric Citrate in ESRD Pilot Project

Conditions:   End Stage Renal Disease;   Chronic Kidney Diseases
Intervention:   Drug: Ferric Citrate
Sponsors:   Sreedhar Mandayam;   Keryx Biopharmaceuticals
Recruiting - verified February 2017

Outcomes in UK ACS Patients Prescribed Ticagrelor

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis

Conditions:   Ischemic Stroke;   Atrial Fibrillation;   Atherothrombosis
Interventions:   Drug: Oral Anticoagulant;   Drug: Antiplatelet Drug
Sponsors:   National Cerebral and Cardiovascular Center;   Network for Clinical Stroke Trials;   The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program
Not yet recruiting - verified February 2017

Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Coronary Thrombosis
Intervention:   Diagnostic Test: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed - verified February 2017

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

Condition:   TIA
Intervention:   Other: Non-Interventional Study
Sponsors:   Andrew Penn;   Genome Canada;   Genome British Columbia;   Genome Alberta;   Heart and Stroke Foundation of Canada;   Stroke Services BC;   Bruker Daltonics;   LifeLabs
Completed - verified February 2017

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Conditions:   Dementia;   Cognition Disorders;   Cerebral Ischemic Events
Interventions:   Drug: Dabigatran Etexilate;   Drug: Warfarin
Sponsors:   Intermountain Health Care, Inc.;   Boehringer Ingelheim
Not yet recruiting - verified January 2017

Remote Ischemic Preconditioning for Cardic Surgery

Conditions:   Myocardial Injury;   Remote Ischemic Preconditioning
Interventions:   Procedure: Remote Ischemic Preconditioning;   Procedure: Control
Sponsor:   Xuzhou Medical University
Recruiting - verified January 2017

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2017

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Condition:   NonHodgkin Lymphoma
Interventions:   Radiation: Standard Arm;   Radiation: Experimental Arm
Sponsor:   Tata Memorial Hospital
Recruiting - verified February 2017

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

Sleep Apnoea in Haemodialysis

Conditions:   Sleep Apnoea;   Renal Failure;   End Stage Kidney Disease;   Sleep Disturbance;   Sleep Disorders;   Sleep
Interventions:   Procedure: Haemodiafiltration post-dilution model;   Procedure: Haemodialysis
Sponsors:   John Hunter Hospital;   Newcastle University;   Hunter Medical Research Institute
Recruiting - verified February 2017

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Condition:   Anemia in Subjects With DD-CKD
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2017

The Effects of Exercise in Patients With Systemic Sclerosis

Conditions:   Systemic Sclerosis;   Raynaud's Phenomenon;   Quality of Life
Interventions:   Other: Exercise intervention - Cycling;   Other: Exercise intervention - arm cranking
Sponsors:   Sheffield Hallam University;   Sheffield Teaching Hospitals NHS Foundation Trust
Recruiting - verified February 2017

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: Darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2017

Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

Condition:   Coronary Stenosis
Interventions:   Device: SUPRAFLEX;   Device: XIENCE
Sponsors:   ECRI bv;   Sahajanand Medical Technologies Pvt. Ltd.
Recruiting - verified January 2017

LEADERS FREE II: BioFreedom™ Pivotal Study

Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
Sponsor:   Biosensors Europe SA
Recruiting - verified February 2017

The TRUST Study - CardioVascular Imaging IMT

Conditions:   Thyroid Dysfunction;   Atherosclerosis;   Heart Failure
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals;   University Hospital, Geneva
Completed - verified February 2017

The TRUST Trial - CardioVascular Imaging ECHO

Conditions:   Thyroid Dysfunction;   Atherosclerosis;   Heart Failure
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals;   University Hospital, Geneva
Completed - verified February 2017

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin

Condition:   Acute Coronary Syndrome
Interventions:   Drug: High dose Rosuvastatin;   Drug: Low dose Rosuvastatin
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

Condition:   Antiplatelet Drugs
Interventions:   Drug: Aspirin only;   Drug: No antiplatelet therapy
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified February 2017

Analysis of the Impact of the Fragility of the Over 70 Years of TIAprognosis

Conditions:   Vascular;   Stoke;   Ischemic;   Transient Ischemic Attack
Intervention:   Other: No intervention
Sponsor:   Groupe Hospitalier Paris Saint Joseph
Recruiting - verified July 2016

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Conditions:   Tachycardia;   Diabetes Mellitus;   Cardiovascular Disease
Intervention:   Device: Subcutaneous Implantable Cardioverter Defibrillator
Sponsors:   Boston Scientific Corporation;   University of Rochester
Suspended - verified February 2017

Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon

Condition:   Hyperglycemia
Intervention:   Device: percutaneous coronary intervention
Sponsor:   Second University of Naples
Completed - verified February 2017

The IPED (Investigation of Palpitations in the ED) Study

Conditions:   Presyncope;   Arrhythmias, Cardiac;   Tachycardia, Supraventricular;   Atrial Fibrillation
Intervention:   Device: AliveCor Heart Monitor
Sponsor:   NHS Lothian
Recruiting - verified January 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2017

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

STAT-STatin and Aspirin in Trauma

Conditions:   Wounds and Injuries;   Venous Thromboembolism
Interventions:   Drug: Aspirin and Rosuvastatin;   Drug: Placebo (for Aspirin and Rosuvastatin)
Sponsor:   Denver Health and Hospital Authority
Recruiting - verified February 2017

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)

Condition:   Coronary In-stent Restenosis
Intervention:   Device: Bioresorbable vascular scaffold
Sponsors:   Spanish Society of Cardiology;   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;   Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP);   Abbott Vascular;   St. Jude Medical;   Terumo Medical Corporation
Not yet recruiting - verified February 2017

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2017

Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN

Conditions:   Heart Failure;   Iron Deficiency;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: Iron (III) isomaltoside 1000
Sponsors:   University of Glasgow;   NHS Greater Glasgow and Clyde
Recruiting - verified February 2017

A Prospective Cohort Study of Aged People for Chronic Diseases

Conditions:   Aging;   Sarcopenia
Intervention:  
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified February 2017

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified February 2017

Coroflex ISAR 2000 Registry

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: stenting with the Coroflex ISAR sirolimus-eluting stent
Sponsors:   B. Braun Melsungen AG;   Charite University, Berlin, Germany
Active, not recruiting - verified February 2017

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial

Conditions:   Stable Angina;   Unstable Angina;   Non-ST Segment Elevation Myocardial Infarction
Interventions:   Device: CX-ISAR;   Device: Orsiro;   Drug: 3-months DAPT;   Drug: 1-year DAPT
Sponsors:   Seoul National University Hospital;   B. Braun Korea Co., Ltd.
Recruiting - verified February 2017

Colchicine in Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Intervention:   Drug: Colchicine vs Placebo
Sponsors:   VA Office of Research and Development;   New York University School of Medicine
Recruiting - verified February 2017

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Orsiro;   Device: Xience
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Recruiting - verified February 2017

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Conditions:   Symptomatic Aortic Stenosis;   Eligible for Transcatheter Aortic Valve Replacement
Interventions:   Drug: Apixaban;   Drug: Standard of care
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Action Research Group;   Bristol-Meyers Squibb & Pfizer
Recruiting - verified February 2017

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Aegis Sentinel Ligation System
Sponsors:   Aegis Medical Innovations;   Applied Health Research Centre
Not yet recruiting - verified February 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified February 2017

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Condition:   Coronary Artery Disease
Interventions:   Drug: Clopidogrel;   Drug: Aspirin plus clopidogrel
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea;   Medtronic;   Chong Kun Dang Pharmaceutical Corp.
Terminated - verified February 2017

Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism

Conditions:   Thyroid Dysfunction;   Mental Fatigue;   Fatigue
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   University College Cork;   University of Lausanne Hospitals
Recruiting - verified February 2017

Korean Coronary Overlapping Stenting Registy

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   The Catholic University of Korea
Recruiting - verified February 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2017

Effectiveness of VistaO2 FLUX Device in Screening of Sleep Apnea/Hypopnea Syndrome

Condition:   Sleep Apnea Syndromes
Intervention:   Device: VistaO2 FLUX device
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Novacor
Recruiting - verified September 2016

Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule

Conditions:   Peripheral Arterial Disease;   Intermittent Claudication
Interventions:   Drug: Danshen Gegen Capsule;   Drug: Placebo
Sponsor:   Chinese University of Hong Kong
Recruiting - verified February 2017

Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function

Condition:   Platelet Aggregation During Acute Myocardial Infarction
Interventions:   Drug: saxagliptin;   Drug: placebo
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute
Recruiting - verified January 2017

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Completed - verified February 2017

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Conditions:   Recurrent Melanoma of the Skin;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease

Condition:   Coronary Atherosclerosis
Intervention:  
Sponsors:   University of Surrey;   Ashford and St. Peter's NHS Trust
Completed - verified February 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Condition:   Cardiogenic Shock
Intervention:   Device: HeartMate PHP
Sponsors:   Thoratec Corporation;   St. Jude Medical
Terminated - verified February 2017

A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Condition:   Myocardial Infarction
Interventions:   Drug: Alteplase;   Other: Placebo
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow;   National Institute for Health Research, United Kingdom
Recruiting - verified September 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor

Conditions:   Hypertension;   Atrial Fibrillation;   Obesity;   Heart Failure;   Atherosclerosis
Intervention:  
Sponsor:   Health Parametrics Inc.
Terminated - verified February 2017

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Completed - verified February 2017

A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI

Conditions:   Heart Diseases;   Cardiovascular Diseases;   3 Vessel Coronary Artery Disease
Interventions:   Device: Coronary stent;   Radiation: Multi Slice Computed Tomography;   Device: instantaneous wave-free ratio;   Device: Fractional flow reserve;   Device: Intravascular Ultrasound
Sponsors:   ECRI bv;   Boston Scientific Corporation;   Volcano Corporation
Active, not recruiting - verified February 2017

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging

Conditions:   Ischemic Heart Disease;   Myocardial Infarction
Intervention:   Drug: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82
Sponsor:   University of Michigan
Completed - verified February 2017

STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

Conditions:   Anterior Acute Myocardial Infarction;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: G-CSF administration
Sponsors:   Heart Care Foundation;   A. Manzoni Hospital;   Centro Cardiologico Monzino
Suspended - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

Condition:   Coronary Restenosis
Interventions:   Device: Everolimus-eluting balloon expandable stent;   Device: paclitaxel eluting balloon
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Terminated - verified February 2017

The Efficacy of Citalopram Treatment in Acute Stroke

Condition:   Stroke, Ischemic
Interventions:   Drug: Citalopram;   Drug: Placebo
Sponsors:   University of Aarhus;   Danish Council for Independent Research;   The Danish Regions Medicine Foundation
Completed - verified December 2016

Intensive Prevention Program After Myocardial Infarction

Conditions:   Myocardial Infarction;   Prevention Harmful Effects
Interventions:   Behavioral: Intensive Prevention Program;   Other: Standard medical and interventional therapy
Sponsors:   Herzzentrum Bremen;   Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
Active, not recruiting - verified February 2017

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified February 2017

Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring

Condition:   Stroke
Interventions:   Other: prolonged ECG monitoring;   Other: standard care
Sponsor:   Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Active, not recruiting - verified February 2017

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute;   Janssen Research & Development, LLC
Recruiting - verified February 2017

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Evaluating New Radiation Techniques for Cardiovascular Imaging

Condition:   Coronary Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 24, 2017

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Conditions:   Obesity;   Overweight
Interventions:   Drug: NB32;   Drug: PBO;   Behavioral: Weight Management Program
Sponsor:   Orexigen Therapeutics, Inc
Terminated - verified April 2016

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition:   Hodgkin Lymphoma, Adult
Interventions:   Drug: Brentuximab vedotin;   Drug: ABVD
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Seattle Genetics, Inc.
Active, not recruiting - verified February 2017

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Condition:   Coronary Artery Disease
Intervention:   Device: percutaneous coronary intervention
Sponsors:   Seung-Jung Park;   Abbott;   CardioVascular Research Foundation, Korea
Terminated - verified February 2017

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Completed - verified February 2017

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified February 2017

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified February 2017

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions:   Severe, Refractory Asthma;   Airway Inflammation;   Airflow Obstruction
Intervention:   Drug: Pioglitazone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 23, 2017

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

Conditions:   Mixed Connective Tissue Disease (MCTD);   Systemic Lupus Erythematosus (SLE)
Intervention:  
Sponsors:   University of Miami;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2017

Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction

Conditions:   Thrombus;   Myocardial Infarction
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Lantheus Medical Imaging
Recruiting - verified February 2017

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Completed - verified February 2017

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified February 14, 2017

Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack

Conditions:   Ischemic Stroke;   Transient Ischemic Attack
Intervention:  
Sponsor:   University Hospital, Tours
Completed - verified February 2017

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Condition:   Graft vs Host Disease
Interventions:   Drug: Topical Dexamethasone;   Drug: Placebo
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 13, 2017

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Condition:   Coronary Artery Disease
Intervention:   Drug: pexelizumab in conjunction with CABG
Sponsors:   Alexion Pharmaceuticals;   Procter and Gamble
Active, not recruiting - verified February 2017

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Conditions:   Cardio-pulmonary Bypass;   Coronary Artery Bypass Graft
Intervention:   Drug: pexelizumab
Sponsor:   Alexion Pharmaceuticals
Completed - verified February 2017

Evaluation of Lipoproteins

Conditions:   Hyperlipidemia;   Hyperlipoproteinemia;   Hypolipoproteinemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 23, 2017